Company Overview
| Stock Name | Immunotech-B |
|---|---|
| Stock Code | 06978 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 中國一家領先的細胞免疫治療生物醫藥公司,逾13年來專注於T細胞免疫治療藥物研發和商業化,核心在研產品EAL®為中國首款獲准進入II期臨床試驗的細胞免疫治療產品。 |
| Listing Date | 2020-07-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市北京經濟技術開發區康定街1號國盛科技園1號樓8層 |
| Business Address (Hong Kong) | 香港銅鑼灣勿地臣街1號時代廣場二座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | eaal.net |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 11.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 11,000 |
| Par Value | To be extracted |
| Offer Period | 2020-06-29 to 2020-07-03 |
| Global Offering Shares | 100,000,000 shares |
| HK Public Offer Shares (Initial) | 10,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 10,000lots (Pool A5,000lots,Pool B5,000lots) |
| International Placing Shares (Initial) | 90,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 500,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 28.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,100,000,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 11,000 |
| 2 lots | 2,000 | HK$ 22,000 |
| 3 lots | 3,000 | HK$ 33,000 |
| 4 lots | 4,000 | HK$ 44,000 |
| 5 lots | 5,000 | HK$ 55,000 |
| 6 lots | 6,000 | HK$ 66,000 |
| 7 lots | 7,000 | HK$ 77,000 |
| 8 lots | 8,000 | HK$ 88,000 |
| 9 lots | 9,000 | HK$ 99,000 |
| 10 lots | 10,000 | HK$ 110,000 |
| 15 lots | 15,000 | HK$ 165,000 |
| 20 lots | 20,000 | HK$ 220,000 |
| 25 lots | 25,000 | HK$ 275,000 |
| 30 lots | 30,000 | HK$ 330,000 |
| 35 lots | 35,000 | HK$ 385,000 |
| 40 lots | 40,000 | HK$ 440,000 |
| 45 lots | 45,000 | HK$ 495,000 |
| 50 lots | 50,000 | HK$ 550,000 |
| 60 lots | 60,000 | HK$ 660,000 |
| 70 lots | 70,000 | HK$ 770,000 |
| 80 lots | 80,000 | HK$ 880,000 |
| 90 lots | 90,000 | HK$ 990,000 |
| 100 lots | 100,000 | HK$ 1,100,000 |
| 150 lots | 150,000 | HK$ 1,650,000 |
| 200 lots | 200,000 | HK$ 2,200,000 |
| 250 lots | 250,000 | HK$ 2,750,000 |
| 300 lots | 300,000 | HK$ 3,300,000 |
| 350 lots | 350,000 | HK$ 3,850,000 |
| 400 lots | 400,000 | HK$ 4,400,000 |
| 450 lots | 450,000 | HK$ 4,950,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 500 lots | 500,000 | HK$ 5,500,000 |
| 600 lots | 600,000 | HK$ 6,600,000 |
| 700 lots | 700,000 | HK$ 7,700,000 |
| 800 lots | 800,000 | HK$ 8,800,000 |
| 900 lots | 900,000 | HK$ 9,900,000 |
| 1,000 lots | 1,000,000 | HK$ 11,000,000 |
| 1,500 lots | 1,500,000 | HK$ 16,500,000 |
| 2,000 lots | 2,000,000 | HK$ 22,000,000 |
| 2,500 lots | 2,500,000 | HK$ 27,500,000 |
| 3,000 lots | 3,000,000 | HK$ 33,000,000 |
| 3,500 lots | 3,500,000 | HK$ 38,500,000 |
| 4,000 lots | 4,000,000 | HK$ 44,000,000 |
| 4,500 lots | 4,500,000 | HK$ 49,500,000 |
| 5,000 lots | 5,000,000 | HK$ 55,000,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 723M |
| Est. Threshold | HK$ 9.37B |
| Analysis Result | HK market cap below threshold, need +1196% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 5,375,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损人民币109.1百万元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 74,800,000 |
| Listing Expenses / Funds Raised | ~6.8% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Other income and gains, net | 8,076 | 6,316 |
| Administrative expenses | -11,666 | -27,760 |
| Operating profit | -33,753 | -106,984 |
| Net finance costs | -1,135 | -2,070 |
| Profit before tax | -34,888 | -109,054 |
| Income tax expense | 0 | 0 |
| Profit for the year | -34,888 | -109,054 |
| Profit attributable to owners | -34,766 | -108,801 |
Balance Sheet
| Item | 2018 | 2019 |
|---|---|---|
| Cash and cash equivalents | 128,332 | 282,247 |
| Inventories | 2,291 | 4,810 |
| Total current assets | 185,761 | 308,150 |
| Total current liabilities | 19,024 | 206,170 |
| Total equity | 216,297 | 170,335 |
| Equity attributable to owners | 214,651 | 168,942 |
Cash Flow Statement
| Item | 2018 | 2019 |
|---|---|---|
| Net cash from operating activities | -44,079 | -95,469 |
| Net cash from investing activities | -50,400 | 25,741 |
| Net cash from financing activities | 214,447 | 217,209 |
| Net increase in cash | 119,968 | 147,481 |
| Depreciation of PP&E | 4,172 | 10,590 |
| Amortisation of intangible assets | 341 | 355 |
| Purchase of PP&E | -35,070 | -13,762 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 15.48 |
|---|---|
| First Day Open | HK$ 13.4 |
| First Day Change | 40.73% |
| First Day Volume | 73620500.0 |
| First Day Turnover | 1099240000.0 |
| Use of Proceeds | 1、約34.2%的所得款項凈額或350.2百萬港元用于投資EAL正在進行的臨床試驗及商業化;
2、約18.9%的所得款項凈額或193.5百萬港元用于擴展EAL的臨床適應癥(不包括肝癌),包括研發開支及就EAL持續技術創新設立新研發中心的建設成本;
3、約33.2%的所得款項凈額或340.0百萬港元用于投資CAR-T-19及TCR-T在研產品系列的臨床試驗,主要包括研發開支;
4、約8.7%的所得款項凈額或89.1百萬港元用于投資我們產品管線中其他在研產品的開發;
5、約5.0%的所得款項凈額或51.2百萬港元用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (13)
建银国际金融有限公司 CE AJO225
Guosen Securities (HK) Capital Company Limited CE AUX600
海通国际证券有限公司 CE AAF806
农银国际证券有限公司 CE ACX411
交银国际证券有限公司 CE APJ121
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
民银证券有限公司 CE APU820
SDIC SECURITIES (HONG KONG) LIMITED CE AUW685
国泰君安证券(香港)有限公司 CE ABY236
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927
ZHONGRONG PT SECURITIES LIMITED CE AAV553
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Joint Lead Managers (18)
建银国际金融有限公司 CE AJO225
Guosen Securities (HK) Capital Company Limited CE AUX600
海通国际证券有限公司 CE AAF806
农银国际证券有限公司 CE ACX411
FTFT International Securities and Futures Limited CE ATR516
交银国际证券有限公司 CE APJ121
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
民银证券有限公司 CE APU820
SDIC SECURITIES (HONG KONG) LIMITED CE AUW685
富途证券国际(香港)有限公司 CE AZT137
国泰君安证券(香港)有限公司 CE ABY236
Wanhai Securities (HK) Limited CE ADS061
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
JOY RICH SECURITIES INVESTMENT LIMITED CE BIH924
SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927
ZHONGRONG PT SECURITIES LIMITED CE AAV553
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
I WIN SECURITIES LIMITED CE BJB315
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Poly Platinum Enterprises Limited | 155,001,000 HKD | — | 14.10% | — | 6 months | 2021-01-10 |
| 2 | 季洪昌 | 38,742,000 HKD | — | 3.50% | — | 6 months | 2021-01-10 |
| 3 | 天士力(香港)医药投资有限公司 | 76,714,000 HKD | — | 7.00% | — | 6 months | 2021-01-10 |
| 4 | 中国联塑集团控股有限公司 | 38,742,000 HKD | — | 3.50% | — | 6 months | 2021-01-10 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 譚錚 | — |
| Company Secretary | 尹夢洋、梁瑞冰 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 譚錚(透過Tan Zheng Ltd)持股36.10%,鄭鉉哲(透過Evodevo)持股26.99%,張蓓妮(透過Bei Ni Ltd)持股6.13%,大灣區共同家園發展基金有限合夥(透過Poly Platinum)持股6.69%。 |
|---|




